RECOMBINANT ERYTHROPOIETIN OVERDOSE

被引：7

作者：

BROWN, KR

CARTER, W

LOMBARDI, GE

机构：

[1] Department of Emergency Medicine, St Luke's-Roosevelt Hospital Center New York

[2] Division of Emergency Medicine, Albert Einstein College of Medicine, Bronx Municipal Hospital Center, Bronx, NY

来源：

AMERICAN JOURNAL OF EMERGENCY MEDICINE | 1993年 / 11卷 / 06期

关键词：

BIOLOGICAL GROWTH FACTORS; ERYTHROPOIETIN; POLYCYTHEMIA;

D O I：

10.1016/0735-6757(93)90017-6

中图分类号：

R4 [临床医学];

学科分类号：

1002 [临床医学]; 100602 [中西医结合临床];

摘要：

Deliberate self-administration of recombinant human erythropoietin (rHuEpo) in a patient without anemia has never been documented. The case of a 62-year-old man who worked in an allied health care field and surreptitiously injected the drug, causing his hematocrit to increase to a dangerously high level is presented. Resultant complications of the misuse of erythropoietin in this patient included worsening hypertension, exacerbation of chronic lung disease and development of new onset angina. Medical management consisted of endotracheal intubation with mechanical ventilation, intravenous hydration, and serial phlebotomy. The unusual possibility of erythropoietin abuse must be added to the differential diagnosis with a patient with unexplained polycythemia. This case highlights the potential abuse of biological growth factors that may mask medical conditions. © 1993.

引用

页码：619 / 621

页数：3

共 24 条

[1]

Spivak, Barnes, Fuchs, Et al., Serum immunoreactive erythropoietin in HIV-infected patients, JAMA, 261, pp. 3104-3107, (1989)

[2]

Fischl, Galpin, Levine, Et al., Recombinant human erythropoietin for patients with AIDS treated with zidovudine, N Engl J Med, 322, pp. 1488-1493, (1990)

[3]

Eschbach, Egrie, Downing, Et al., Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial, N Engl J Med, 316, pp. 73-78, (1987)

[4]

Eschbach, Abdulhadi, Browne, Et al., Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial, Ann Intern Med, 111, pp. 992-1000, (1989)

[5]

Winearls, Oliver, Pippard, Et al., Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis, Lancet, 2, pp. 1175-1178, (1986)

[6]

Erslev, Erythropoietin, N Engl J Med, 324, pp. 1339-1344, (1991)

[7]

Goodnough, Rudnick, Price, Et al., Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy, N Engl J Med, 321, pp. 1163-1168, (1989)

[8]

Adamson, Vapnek, Recombinant erythropoietin to improve athletic performance, N Engl J Med, 324, (1991)

[9]

Undetectable dialysis drug tied to athletes' deaths, Los Angeles Times, (1990)

[10]

Klein, Blood transfusion and athletics: Games people play, N Engl J Med, 312, pp. 854-856, (1985)

← 1 2 3 →